PMID- 24714301
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240420
IS  - 1108-7471 (Print)
IS  - 1792-7463 (Electronic)
IS  - 1108-7471 (Linking)
VI  - 26
IP  - 3
DP  - 2013
TI  - Recent advances on the management of patients with non-variceal upper 
      gastrointestinal bleeding.
PG  - 191-197
AB  - Non-variceal upper gastrointestinal bleeding is a common emergency associated 
      with significant morbidity and mortality. The mainstays of therapy include prompt 
      resuscitation, early risk stratification, and appropriate access to endoscopy. 
      Patients with high-risk endoscopic findings should receive endoscopic hemostasis 
      with a modality of established efficacy. The pillar of post-endoscopic therapy is 
      acid-suppression via proton pump inhibitors (PPI), although the optimal dose and 
      route of administration are still unclear. Post-discharge management of patients 
      with peptic ulcers includes standard oral PPI treatment and eradication of 
      Helicobacter pylori infection. The risk of recurrent bleeding should be carefully 
      considered and appropriate gastroprotection should be offered when non-steroid 
      anti-inflammatory drugs, anti-platelet agents, and/or anticoagulation need to be 
      used. This review seeks to survey new evidence in the management of non-variceal 
      upper gastrointestinal bleeding that has emerged in the past 3 years and put it 
      into context with recommendations from recent practice guidelines.
FAU - Sheasgreen, Christopher
AU  - Sheasgreen C
AD  - Division of Internal Medicine (Christopher Sheasgreen), McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Leontiadis, Grigorios I
AU  - Leontiadis GI
AD  - Division of Gastroenterology (Grigorios I. Leontiadis), McMaster University, 
      Hamilton, Ontario, Canada.
LA  - eng
PT  - Review
PL  - Greece
TA  - Ann Gastroenterol
JT  - Annals of gastroenterology
JID - 101121847
PMC - PMC3959446
OTO - NOTNLM
OT  - Non-variceal upper gastrointestinal bleeding
OT  - endoscopic hemostasis
OT  - proton pump inhibitors
OT  - risk stratification
COIS- Conflict of Interest: The authors have not received funding from any sources for 
      the conduct of this review paper. Dr. Sheasgreen has no conflicts of interest. 
      Dr. Leontiadis has received a research grand from AstraZeneca for a different 
      project
EDAT- 2013/01/01 00:00
MHDA- 2013/01/01 00:01
PMCR- 2013/01/01
CRDT- 2014/04/10 06:00
PHST- 2013/01/18 00:00 [received]
PHST- 2013/03/19 00:00 [accepted]
PHST- 2014/04/10 06:00 [entrez]
PHST- 2013/01/01 00:00 [pubmed]
PHST- 2013/01/01 00:01 [medline]
PHST- 2013/01/01 00:00 [pmc-release]
AID - AnnGastroenterol-26-191 [pii]
PST - ppublish
SO  - Ann Gastroenterol. 2013;26(3):191-197.